Most PMHNPs I talk to describe the same ADHD prescribing bottleneck. Stimulants work well for most patients, but a growing share either can’t tolerate them, shouldn’t take them because of cardiac or substance use concerns, or simply can’t get them filled during the ongoing supply shortages the FDA has kept on its official shortage list since 2022. The current non-stimulant options — atomoxetine, viloxazine, guanfacine extended-release — are useful, but patients and prescribers both know they work differently. They’re slower. They don’t touch dopamine. And the response rates, candidly, are not what we see with stimulants.
That’s about to change. On January 27, 2026, the FDA accepted Otsuka’s new drug application for centanafadine for priority review, with a PDUFA target action date of July 24, 2026. If it clears that date — and priority review usually signals a compound the agency wants to move — PMHNPs prescribing for ADHD will have a genuinely new tool for the first time in years: a non-stimulant that modulates dopamine, norepinephrine, and serotonin together, and that showed stimulant-like onset in Phase 3 trials.
Here’s what’s actually on the table, what the evidence shows, and what you should start doing now to prepare your practice.
What Centanafadine Actually Is
Centanafadine is a serotonin-norepinephrine-dopamine triple reuptake inhibitor, sometimes called an NDSRI in the literature. Mechanistically, it sits in a space nothing else in the ADHD armamentarium occupies. Methylphenidate and amphetamines hit dopamine and norepinephrine but do so through release plus reuptake inhibition with rapid CNS onset. Atomoxetine and viloxazine primarily act on norepinephrine. Nothing currently on the ADHD market modulates all three monoamines together, and nothing in the non-stimulant category has demonstrated onset at week one.
That matters because the dopaminergic effect is, in part, what gives stimulants their efficacy. Centanafadine’s triple mechanism is why coverage from Psychiatric Times, ADDitude Magazine, and Pharmacy Times has described it as a potential non-stimulant that behaves more like a stimulant, at least in terms of clinical response timing.
The Evidence Base Behind the NDA
The NDA submission is backed by four Phase 3 randomized controlled trials — extended-release formulations in children and adolescents, and sustained-release in adults. The pediatric and adolescent trials used the ADHD Rating Scale-5 (ADHD-RS-5) as the primary endpoint. The adult trials used the ADHD Investigator Symptom Rating Scale (AISRS). Across the program, centanafadine produced statistically significant and clinically meaningful symptom improvements versus placebo.
Two details jumped out at me when I worked through the data. First, onset. Separation from placebo was observable by week one and maintained through week six — that is a different profile from the four-to-eight week ramp we typically counsel patients to expect with atomoxetine or viloxazine. Second, breadth of study. The program enrolled children as young as six and adults across multiple Phase 3 cohorts, and the FDA is reviewing the application for all three age groups simultaneously. If approved, you’d have one molecule with data and labeling covering pediatrics through adults — an unusual simultaneous launch profile.
Independent sources covering the program include Psychiatric Times’ NDA-submission analysis, ADDitude Magazine’s clinical breakdown of the Phase 3 results, and the FDA’s own priority review designation, which the agency doesn’t hand out lightly. Psychiatric News flagged the pending July 24 decision in its January 2026 MedCheck column alongside other near-term regulatory actions PMHNPs should be tracking.

Safety and Tolerability — What the Trials Actually Showed
Across the Phase 3 program, centanafadine was generally well tolerated. In children and adolescents, the most commonly reported adverse events were decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence. In adults, decreased appetite and headache were the most common. Nothing in the public data suggests the dramatic cardiovascular or insomnia signals that have historically made some patients and parents cautious about stimulants.
The tolerability question for a triple reuptake inhibitor is, of course, serotonergic side effects. Nausea showing up in the pediatric data is consistent with that mechanism. We don’t yet have full labeling, so serotonin syndrome risk in combination with SSRIs, SNRIs, or MAOIs will need to be watched closely once we see the package insert. If you have patients on complicated polypharmacy — particularly those on multiple serotonergic agents — that’s a conversation to start thinking through now.
Why This Matters Specifically for PMHNPs in Private Practice
Three realities define ADHD prescribing in PMHNP private practice right now, and centanafadine speaks to all of them.
First, the stimulant supply situation is still unresolved. The FDA has kept Schedule II stimulant shortages on its official shortage list through 2025 and into 2026. Every PMHNP I know has had patients cycling through pharmacies trying to get their mixed amphetamine salts or methylphenidate filled. A non-controlled alternative with stimulant-like onset would reduce that operational burden in a real way.
Second, DEA scrutiny of controlled-substance telehealth prescribing keeps tightening. Even with the DEA’s recent extension of telehealth flexibilities through the end of 2026, the direction of travel for controlled-substance prescribing in virtual practice is more oversight, not less. A non-controlled ADHD option with real efficacy gives telehealth-heavy practices a clinically defensible path for patients who don’t want or can’t safely take Schedule II medications.
Third, we are seeing an adult ADHD diagnosis surge that shows no signs of slowing. More adults are being evaluated, and a meaningful subset present with cardiovascular risk factors, substance use histories, anxiety that worsens on stimulants, or simple stimulant intolerance. For those patients, current non-stimulants often underdeliver. A triple reuptake inhibitor with demonstrated adult Phase 3 efficacy may finally close that gap.

What to Do in Your Practice Before July 24
You don’t need to wait for FDA action to start preparing. A few concrete moves will put you ahead of the curve.
Update your ADHD intake documentation now. Make sure you’re capturing stimulant response history, intolerance reasons, cardiovascular risk factors, and current psychiatric medication list in a way that will let you quickly identify patients who might be good candidates for a new option. If your EMR doesn’t have structured fields for stimulant trial history, build them or add standardized smart-phrases.
Brief your front office and billing staff. If centanafadine is approved, there will be a window where payers don’t have it on formulary and prior authorizations will be the default. Have your PA workflow documented: which pharmacy benefit managers require step therapy, which require documented stimulant trials, and how you’ll submit appeals. The AANP has practical PA templates for new psychiatric medications that are worth adapting.
Build your patient communication in advance. When a new medication launches, patients read about it before you do. Having a short, plain-English handout explaining what the drug is, who it might help, and what the evidence shows prevents you from being on the defensive during appointments. Keep it separate from any drug company material.
Talk to your collaborating physician now if your state requires one. If you’re in a reduced- or restricted-practice state, your collaborator may have views about adopting brand-new psychotropics early. It’s a much easier conversation before the drug is available than the first time you’re trying to prescribe it.
Who Is Centanafadine Actually For
Assuming approval matches the Phase 3 label, I’d expect the practical use case to fall into a few buckets.
Adults with moderate-to-severe ADHD who have failed, not tolerated, or been deemed inappropriate for stimulants. Patients with cardiovascular risk factors, substance use history, or recurrent stimulant-associated anxiety. Adolescents whose parents are unwilling to consider a controlled substance. And — importantly — patients whose ADHD coexists with depressive or anxiety symptoms, where the serotonergic component might theoretically confer some benefit, though that’s speculative until we see broader real-world data.
It probably will not replace stimulants as first line for uncomplicated cases. Stimulants remain extraordinarily effective, and PMHNPs are generally comfortable with their risk-benefit profile. But as a non-stimulant option with a meaningfully different mechanism and faster onset, centanafadine could change how we sequence therapy — particularly in patients we currently send to atomoxetine or viloxazine after stimulant failure.

The Open Questions
Several things we don’t yet know matter for real-world prescribing. Head-to-head data against atomoxetine or stimulants is not yet public. Long-term cardiovascular data is limited compared to what we have on methylphenidate. Whether centanafadine will be scheduled by DEA, and if so what schedule, remains to be determined; the current positioning suggests non-controlled, but the final determination post-approval is what counts. And payer coverage — realistically, expect a formulary fight for the first 12 to 18 months post-launch.
A related question is titration. Phase 3 dosing protocols used defined titration schedules, but how clinicians will titrate in the real world — and whether there’s a meaningful dose-response effect at the higher end — is something we’ll only learn from post-approval clinical experience.
Bottom Line
July 24, 2026 is the date to mark. If centanafadine clears, PMHNPs in private practice will have a genuinely novel ADHD tool available for the first time in years — one that addresses real gaps in current prescribing and could meaningfully reduce the operational drag of controlled-substance workflows. The smart move right now is to get your documentation, your staff, and your patient communication ready so you’re not scrambling in week one. The PMHNPs who prepare ahead of a drug launch consistently get the best early outcomes, the smoothest payer experience, and the most confident patient conversations.
If you want more practical guidance on staying ahead of the clinical and regulatory changes that hit PMHNP private practice, the PMHNP Website publishes new content on this stuff weekly.
